Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 175 clinical trials
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor. One of the approaches to augment graft-versus-leukemia effect the use of post-transplantation bendamustine in graft-versus-host disease prophylaxis. Despite high frequency of responses and durable remissions after this approach majority of patients …

cell transplantation
cyclophosphamide
blast cells
hla-a
leukemia
  • 0 views
  • 19 Apr, 2022
  • 1 location
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).

myelofibrosis
cell transplantation
leukemia
lymphoma
ejection fraction
  • 0 views
  • 06 May, 2022
  • 1 location
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a …

hydrea
gilbert's syndrome
cell transplantation
leukemia
  • 0 views
  • 25 Mar, 2022
  • 1 location
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment

  • 17 views
  • 21 Feb, 2022
  • 1 location
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity improves cognitive function in older adults and survivors of other cancers. We hypothesize that increasing physical activity can …

cancer
cell transplantation
  • 0 views
  • 15 Dec, 2021
  • 1 location
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: Venetoclax Decitabine Navitoclax

venetoclax
myelofibrosis
gilbert's syndrome
blast cells
decitabine
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT). This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years

tacrolimus
myelofibrosis
cell transplantation
cyclophosphamide
blast cells
  • 4 views
  • 08 Jul, 2022
  • 2 locations
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used …

colony stimulating factor
blast cells
cancer
myeloid leukemia
ejection fraction
  • 0 views
  • 26 Feb, 2022
  • 1 location
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a type of genetic mutation (change). Chemotherapy drugs, such as CPX-351, work …

refractory acute myeloid leukemia (aml)
cancer
myeloid leukemia
cytarabine
direct bilirubin
  • 1 views
  • 08 Jul, 2022
  • 1 location
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced intensity conditioning (RIC) has been increasingly adopted as a modality to allow preparative conditioning pre-transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study Reduced intensity conditioning (RIC) conditioning is used and followed by match aploidentical donor peripheral blood …

tacrolimus
myelofibrosis
cell transplantation
cyclophosphamide
colony stimulating factor
  • 0 views
  • 04 Nov, 2021
  • 1 location